Antiretroviral Reference Tables

July 2006; updated February 2008

Chapter Contents

Drug Characteristics

Regimen Selection

Drug Interactions

Adverse Effects

Special Situations

Table Sources

Drug Characteristics

• Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (DHHS: Table 10)
• Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (DHHS: Table 11)
• Characteristics of Protease Inhibitors (PIs) (DHHS: Table 12)
• Characteristics of Fusion Inhibitors (DHHS: Table 13)
• Characteristics of CCR5 Antagonists (DHHS: Table 14)
• Characteristics of Integrase Inhibitors (DHHS: Table 15)

Regimen Selection

• Antiretroviral Components Recommended for Treatment of HIV-1 Infection in Treatment-Naive Patients (DHHS: Table 6)
• Antiretroviral Components Not Recommended as Initial Therapy (DHHS: Table 7)
• Antiretroviral Regimens or Components That Should Not Be Offered At Any Time (DHHS: Table 8)
• Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy (DHHS: Table 9)
• Options for Once-Daily Dosing of Antiretrovirals (NRC: Coffey)

Drug Interactions

• Dosage Adjustments for ARV-ARV Drug Interactions (NRC: Coffey, McNicholl)
• Drugs That Should Not Be Used with PI, NNRTI, or CCR5 Antagonist Antiretrovirals (DHHS: Table 21)
• Drug Interactions Among Antiretrovirals and Other Drugs: PIs and Maraviroc (DHHS: Table 22a)
• Drug Interactions Among Antiretrovirals and Other Drugs: NNRTIs (DHHS: Table 22b)
• Drug Interactions Among Antiretrovirals and Other Drugs: NRTIs (DHHS: Table 22c)

Adverse Effects

• Adverse Events of Antiretroviral Drugs (NRC: Coffey, McNicholl)
• Potentially Life-Threatening and Serious Adverse Events (DHHS: Table 18a)
• Adverse Events with Potential Long-Term Complications (DHHS: Table 18b)
• Adverse Effects Compromising Quality of Life and/or with Potential Impact on Medication Adherence (DHHS: Table 18c)
• Adverse Drug Reactions and Related "Black Box Warnings" in Product Labeling for Antiretroviral Agents (DHHS: Table 20)

Special Situations

• Identifying, Diagnosing, and Managing Acute HIV-1 Infection (DHHS: Table 25)
• Preclinical and Clinical Data Relevant to the Use of Antiretrovirals during Pregnancy (DHHS: Table 26)
• Dosing for Ritonavir-Boosted Protease Inhibitors (NRC: Coffey, McNicholl)
• Dosing of Antiretroviral Drugs in Adults with Renal Insufficiency and Hemodialysis (NRC: McNicholl, Rodriguez)

Table Sources

• DHHS = U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents . January 29, 2008. Available online at aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7.
• NRC = AETC National Resource Center , Antiretroviral Reference Tables for Clinicians. Available online at aidsetc.org.